Journal of Clinical Oncology · 2003 · 75 citations · 30 references
MedicineOncologyPharmacologyBreast OncologyCancer PharmacologyChemotherapyBreast Cancer PharmacotherapyChemotherapy Drug AdministrationCombination ChemotherapyHigh-dose ChemotherapyMetastatic Breast CancerAnthracycline-based ChemotherapyBreast Cancer ChemotherapyCyclophosphamide-based TherapyDisease-free Survival AnalysisDisease-free Survival AssessmentGranulocyte Colony-stimulating Factor AdministrationHigh-dose Chemotherapy AdministrationMetastatic Breast Cancer Treatment
PURPOSE: Lonidamine (LND) can enhance the activity of anthracyclines in patients with metastatic breast cancer. A multicenter, prospective, randomized trial was designed to determine whether the association of LND with high-dose epirubicin plus cyclophosphamide (EC) could improve disease-free survival (DFS) in patients with early breast cancer (BC) compared with EC alone. Granulocyte colony-stimulating factor (G-CSF) was added to maintain the EC dose-intensity. PATIENTS AND METHODS: From October 1991 to April 1994, 506 patients with stage I/II BC were randomly assigned to four groups: (A) epirubicin 120 mg/m2 and cyclophosphamide 600 mg/m2 administered intravenously on day 1 every 21 days for four cycles (124 patients); (B) EC plus LND 450 mg/d administered orally (125 patients); (C) EC plus G-CSF administered subcutaneously (129 patients); (D) EC plus LND plus G-CSF (128 patients). RESULTS: Median follow-up was 55 months. Five-year DFS rate was similar for LND (B+D groups; 69.6%) versus non-LND arms (A+C groups; 70.3%) and G-CSF (C+D groups; 67.2%) versus non-G-CSF arms (A+B groups; 72.9%). Five-year overall survival (OS) was comparable in LND (79.1%) versus non-LND arms (81.3%) and in G-CSF (80.6%) versus non-G-CSF arms (79.6%). DFS and OS distributions in LND and G-CSF arms did not change according to tumor size, node, receptor, and menopausal status. G-CSF dramatically reduced hematologic toxicity without having a significant impact on dose-intensity (98.1% v 95.5% for C+D and A+B groups, respectively). CONCLUSION: EC is active and well tolerated in patients with early breast cancer. The addition of LND or G-CSF does not improve DFS or OS.
30
Bernard Fisher, Ann Brown, N V Dimitrov et al. · Journal of Clinical Oncology · 1990 · 627 citations
Medicine, Oncology, Pharmacotherapy +17
Mark N. Levine, V. Bramwell, Kathleen I. Pritchard et al. · Journal of Clinical Oncology · 1998 · 623 citations
Medicine, Oncology, Pharmacotherapy +10
Journal of Clinical Oncology · 2001 · 254 citations
Medicine, Oncology, Pharmacology +17
Bernard Fisher, James J. Dignam, Eleftherios P. Mamounas et al. · Journal of Clinical Oncology · 1996 · 235 citations
Medicine, Oncology, Pharmacology +17